Case Report: MOGAD presenting as infectious meningoencephalitis with concomitant low-titer GFAP-IgG of uncertain significance
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) and autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy (GFAP-A) have recently garnered substantial research interest. Nevertheless, instances of concomitant positivity for MOG-IgG and GFAP-IgG, particularly those presenting as infectious meningoencephalitis, remain rare. This report details the case of a 54-year-old man who presented with headache and fever, with an initial clinical presentation suggestive of infectious meningoencephalitis despite the absence of an identifiable pathogen. Low titers (1:10) of MOG-IgG and GFAP-IgG were detected in both serum and cerebrospinal fluid (CSF). MRI of the brain revealed an old post-traumatic encephalomalacic lesion in the right parietal lobe. The patient initially improved with antiviral therapy but subsequently deteriorated, with cognitive decline, visual blurring in the left eye, and bilateral leg weakness. Further testing revealed a marked increase in serum MOG-IgG titer, from 1:10 to 1:320 within one month. A gadolinium-enhanced brain MRI demonstrated new lesions in the brainstem, medial aspects of the bilateral temporal lobes, and the left parietal lobe. Spinal MRI revealed multiple short-segment signal abnormalities in the cervical and thoracic spinal cord, with partial enhancement of the lesions and meninges. Orbital MRI showed edema and thickening of the left optic nerve. The patient was diagnosed with MOGAD, presenting as infectious meningoencephalitis, with concomitant low-titer GFAP-IgG of uncertain significance. The treatment regimen comprised high-dose methylprednisolone and efgartigimod, followed by a tapering course of oral prednisolone and the initiation of rituximab. The patient exhibited symptomatic improvement and sustained remission under combined immunotherapy. This case highlights that MOGAD with concomitant low-titer GFAP-IgG may not initially present its full clinical spectrum. Clinical, radiological, and laboratory features may evolve over time. Therefore, diagnosis should extend beyond the initial presumed etiology, with ongoing reassessment as new evidence emerges.
Authors
- Mei Jin
- Rui Ma (ORCID: https://orcid.org/0009-0002-7253-3941)
- Xiaoyan Niu
- Xiao Yang
- Ying Wang
- Dewen Ma
- Qiang Liu
Institutions
- Ningxia Medical University (CN)
- Ningxia Medical University General Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-13
- DOI
- https://doi.org/10.3389/fimmu.2026.1976358
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00